Engineered Stem Cell Booster Breaks Pathological Barriers to Treat Chronic Pancreatitis

H Han Han (Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, United States) B Bi‐Te Chen (State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 P. R. China) Y Yang Liu L Liang Qi (National Engineering Research Center of Lower-Carbon Catalysis Technology) L Lei Xing (Department of Radiation Oncology, Stanford University) H Hui Wang M Min Zhao C Chen Zhang (Shenzhen Institute for Quantum Science and Engineering, Department of Chemistry, and Department of Physics) P Ping Yu (Beijing National Laboratory for Molecular Science, Key Laboratory of Analytical Chemistry for Living Biosystems) N Ning Wei (Jiangsu Key Laboratory of Advanced Food Manufacturing Equipment and Technology) J Jing Wang (Hunan Cancer Hospital Changsha China) F Fang Zhou (Institute of Hydrobiology, Chinese Academy of Sciences) G Guang‐Ji Wang (Key Laboratory of Drug Metabolism and Pharmacokinetics Haihe Laboratory of Cell Ecosystem State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China) X Xian‐Wu Cheng (Department of Cardiology and Hypertension Yanbian University Hospital Yanji 133000 P. R. China) Z Zhang‐Jian Huang (State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases Center of Drug Discovery China Pharmaceutical University Nanjing 210009 P. R. China) L Ling Li H Hu‐Lin Jiang (State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 China)

Abstract

AbstractChronic pancreatitis (CP) is a long‐standing progressive fibrosis and has long been considered incurable, which remains a heavy health burden worldwide. Mesenchymal stem cells (MSCs) with anti‐fibrosis properties are currently used in the treatment of fibroinflammatory diseases. However, its therapeutic effect is limited mainly due to two main types of pathological barriers in CP: 1) Fibrotic collagen hinders cell delivery, and 2) Malignant microenvironment attacks cell inactivation. Here, a MSCs‐based exogenous nitric oxide (NO) delivery system (MSCs‐Lip@RNO) is constructed. In the MSCs‐Lip@RNO, NO not only can be a cell booster to regulate collagen fibers, relieve the vascular compression and enhance the accumulation of MSCs in the whole pancreas, but also can form a protective gas layer on the cell surface, which enhances the therapeutic effect of MSCs. In the CP rat model, the pancreatic injury and fibrosis are reduced with 7 days after a single dose administration of this long‐acting MSCs. Collectively, this study offers a promising strategy for enhancing the delivery and therapeutic efficacy of MSCs to break pathological barriers in CP treatment.

Article Details

Volume / Issue Vol. 37, Issue 14
Published April 01, 2025
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (17)

H

Han Han

Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, United States

B

Bi‐Te Chen

State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 P. R. China

Y

Yang Liu

L

Liang Qi

National Engineering Research Center of Lower-Carbon Catalysis Technology

L

Lei Xing

Department of Radiation Oncology, Stanford University

H

Hui Wang

M

Min Zhao

C

Chen Zhang

Shenzhen Institute for Quantum Science and Engineering, Department of Chemistry, and Department of Physics

P

Ping Yu

Beijing National Laboratory for Molecular Science, Key Laboratory of Analytical Chemistry for Living Biosystems

N

Ning Wei

Jiangsu Key Laboratory of Advanced Food Manufacturing Equipment and Technology

J

Jing Wang

Hunan Cancer Hospital Changsha China

F

Fang Zhou

Institute of Hydrobiology, Chinese Academy of Sciences

G

Guang‐Ji Wang

Key Laboratory of Drug Metabolism and Pharmacokinetics Haihe Laboratory of Cell Ecosystem State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China

X

Xian‐Wu Cheng

Department of Cardiology and Hypertension Yanbian University Hospital Yanji 133000 P. R. China

Z

Zhang‐Jian Huang

State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases Center of Drug Discovery China Pharmaceutical University Nanjing 210009 P. R. China

L

Ling Li

H

Hu‐Lin Jiang

State Key Laboratory of Natural Medicines Department of Pharmaceutics China Pharmaceutical University Nanjing 210009 China